Alto Neuroscience, Inc. Preferred Stock, Shares Authorized
Alto Neuroscience, Inc. (ANRO) had Preferred Stock, Shares Authorized of 10.00 million shares as of 2024-02-06, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Stockholders' Equity, Number of Shares, Par Value and Other Disclosure › Preferred Stock, Number of Shares, Par Value and Other Disclosure
us-gaap:PreferredStockSharesAuthorized · last filed 2026-08-12
- 2024-02-06: Preferred Stock, Shares Authorized 10.00M shares.
| Period end | Preferred Stock, Shares Authorized |
|---|---|
| 2024-02-06 | 10.00M shares 10-Q · filed 2026-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |